Scienture Holdings Raises $3.9M in Registered Direct Offering

Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors to buy 3,225,000 shares of common stock at $1.20 per share, raising approximately $3.9 million before deducting fees and expenses. The offering is expected to close on August 15, 2025, subject to customary conditions. Maxim Group LLC is acting as sole placement agent.

Scienture Holdings, Inc. (Nasdaq: SCNX), a holding company focused on developing and distributing novel specialty pharmaceutical products, has entered into a securities purchase agreement with institutional investors to buy 3,225,000 shares of common stock at $1.20 per share. The gross proceeds from this offering, expected to be approximately $3.9 million, will be used to fund the company's ongoing operations and product development efforts [1].

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198), previously filed with the U.S. Securities and Exchange Commission (SEC) on August 1, 2025, and declared effective on August 8, 2025. The shares may be offered only by means of a prospectus. A prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov [1].

Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on August 15, 2025, subject to customary closing conditions [1].

Scienture Holdings, Inc. is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians, and caregivers by offering novel specialty products to satisfy unmet market needs. The company's wholly owned subsidiary, Scienture, LLC, is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals. The assets in development at Scienture are across various therapeutics areas, indications, and market segments [1].

The company's press release also includes forward-looking statements, which are subject to risks and uncertainties. These include the company's ability to satisfy closing conditions for the registered direct offering, risks relating to agreements with third parties, and the outcome of any current or future legal proceedings [1].

For more information, investors can visit the company's website at www.scienture.com or contact Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, by telephone at (212) 895-3745, or by email at syndicate@maximgrp.com [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9512433/scienture-holdings-inc-announces-pricing-of-39-million-registered-direct-offering-of-common-stock